KRT8

(redirected from CK8)

KRT8

A gene on chromosome 12q13.13 that encodes a type-II cytokeratin that heteropolymerises to form intermediate filaments in epithelial cell cytoplasm. The KRT 8 typically dimerises with KRT 18 to form an intermediate filament in simple single-layered epithelial cells. KRT8  plays a role in maintaining cellular structural integrity, in signal
transduction and cell differentiation.

Molecular pathology
KRT8 mutations cause cryptogenic cirrhosis.
Mentioned in ?
References in periodicals archive ?
7,8) In addition, they are positive for pancytokeratin AE1/AE3 (AE1/AE3), CK7, CK8, CK18, and STAT5a.
The lining epithelia exhibited a negative expression pattern for CK8 and CK18.
Immunohistochemistry revealed positivity of tumor for CD117, CK8 [Figure 1]e, CD10, EMA, Pax-8, CK AE1/3, CK cocktail and negative for HMB45, SMA [Figure 1]f, Melan-A (A103), TFE3, vimentin, CK7, and Cathepsin K.
2) and low-molecular weight cytokeratins (CK7, CK8, CK19).
5] The epithelial component of the tumour typically stains with a number of cytokeratin (CK) markers, namely AE1/AE3, CK8, CK7 and CK20.
En la mama se encuentran diferentes tipos de marcadores usados en inmunohistoquimica que identifican las celulas luminales: citoqueratinas CK7, CK8, CK18, CK19; celulas basales: CK5/6, CK14, CK17; celulas mioepiteliales: CK5, CK14, CK17, SMA, SM, calponina, p63; y otros marcadores como la proteina s-100, CD10, caderina, receptores de estrogenos, progesterona, y HER2.
In view of the results from the study, we can use some IHC markers like CK8 to offer a better analysis of morphologically undifferentiated lobular and duc-tal malignancies.
34) CK19 and CK8 are markers of sequential premalignant changes in head and neck carcinogenesis.
Samples were counterstained with Harris' hematoxylin (Biopur, Rosario, Argentina) for BrdU labeling or with Mayer's hematoxylin for CK8, p63, and RMCP-I detection, and mounted with permanent mounting medium (PMyR, Buenos Aires, Argentina).
81) Immunostain of cytokeratin (AE1/AE3, CK7, CK8, and CK18) is helpful in identifying infiltrating tumor cells when there are only a few tumor cells, especially in patients who have undergone neoadjuvant therapy.
3) Special techniques such as Ki-67 staining and immunohistochemistry studies for cytokeratin subtypes CK8, CK7, and CK19 might guide in pathologically differentiating SNUC from nasopharyngeal carcinoma and squamous cell carcinoma.
Epithelial antigens (CK7, CK8, CK18, and EMA) are also expressed in some tumors.